146 related articles for article (PubMed ID: 38151993)
1. Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.
Ma Z; Gu Q; Dai Y; Wang Q; Shi W; Jiao Z
Cancer Sci; 2024 Mar; 115(3):820-835. PubMed ID: 38151993
[TBL] [Abstract][Full Text] [Related]
2. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract][Full Text] [Related]
3. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
[TBL] [Abstract][Full Text] [Related]
4. EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation.
Yin H; Zhang C; Wei Z; He W; Xu N; Xu Y; Li T; Ren K; Kuang Y; Zhu X; Yuan F; Yu H; Gou X
Cell Death Dis; 2022 Jan; 13(1):39. PubMed ID: 35013128
[TBL] [Abstract][Full Text] [Related]
5. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer.
Yang C; Hu JF; Zhan Q; Wang ZW; Li G; Pan JJ; Huang L; Liao CY; Huang Y; Tian YF; Shen BY; Chen JZ; Wang YD; Chen S
Genomics; 2021 Mar; 113(2):827-842. PubMed ID: 33515675
[TBL] [Abstract][Full Text] [Related]
6. SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line.
Feng W; Li HC; Xu K; Chen YF; Pan LY; Mei Y; Cai H; Jiang YM; Chen T; Feng DX
Gene; 2016 Aug; 587(1):91-7. PubMed ID: 27129942
[TBL] [Abstract][Full Text] [Related]
7. SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with poor prognosis.
Peng C; Zhao H; Song Y; Chen W; Wang X; Liu X; Zhang C; Zhao J; Li J; Cheng G; Wu D; Gao C; Wang X
J Exp Clin Cancer Res; 2017 Oct; 36(1):141. PubMed ID: 29020987
[TBL] [Abstract][Full Text] [Related]
8. Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway.
Dai Y; Hu C; Zhou H; Liu W; Lai W; Xu R; Liao J; Wang J; Li G; Zhang R
FEBS J; 2023 Dec; 290(24):5720-5743. PubMed ID: 37581853
[TBL] [Abstract][Full Text] [Related]
9. Functional roles of the SHCBP1 and KIF23 interaction in modulating the cell-cycle and cisplatin resistance of head and neck squamous cell carcinoma.
Sun Y; Pan H; He Y; Hu C; Gu Y
Head Neck; 2022 Mar; 44(3):591-605. PubMed ID: 34918847
[TBL] [Abstract][Full Text] [Related]
10. SHCBP1 is a novel target and exhibits tumor‑promoting effects in gastric cancer.
Dong YD; Yuan YL; Yu HB; Tian GJ; Li DY
Oncol Rep; 2019 Mar; 41(3):1649-1657. PubMed ID: 30592290
[TBL] [Abstract][Full Text] [Related]
11. Biological functions and therapeutic potential of SHCBP1 in human cancer.
Lin Y; Cai H
Biomed Pharmacother; 2023 Apr; 160():114362. PubMed ID: 36739763
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
Peng C; Zhao H; Chen W; Song Y; Wang X; Li J; Qiao Y; Wu D; Ma S; Wang X; Gao C
Oncotarget; 2016 Oct; 7(41):66822-66834. PubMed ID: 27572315
[TBL] [Abstract][Full Text] [Related]
13. SHCBP1 promotes cisplatin induced apoptosis resistance, migration and invasion through activating Wnt pathway.
Zou A; Wu A; Luo M; Zhou C; Lu Y; Yu X
Life Sci; 2019 Oct; 235():116798. PubMed ID: 31472149
[TBL] [Abstract][Full Text] [Related]
14. The Role of Shcbp1 in Signaling and Disease.
Zhang GY; Ma ZJ; Wang L; Sun RF; Jiang XY; Yang XJ; Long B; Ye HL; Zhang SZ; Yu ZY; Shi WG; Jiao ZY
Curr Cancer Drug Targets; 2019; 19(11):854-862. PubMed ID: 31250756
[TBL] [Abstract][Full Text] [Related]
15. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
[TBL] [Abstract][Full Text] [Related]
16. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
[TBL] [Abstract][Full Text] [Related]
17. SHCBP1 regulates STAT3/c-Myc signaling activation to promote tumor progression in penile cancer.
Mo M; Tong S; Yin H; Jin Z; Zu X; Hu X
Am J Cancer Res; 2020; 10(10):3138-3156. PubMed ID: 33163262
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of SHCBP1 promotes migration and invasion in gliomas by activating the NF-κB signaling pathway.
Zhou Y; Tan Z; Chen K; Wu W; Zhu J; Wu G; Cao L; Zhang X; Zeng X; Li J; Zhang W
Mol Carcinog; 2018 Sep; 57(9):1181-1190. PubMed ID: 29745440
[TBL] [Abstract][Full Text] [Related]
19. AZD5582, an IAP antagonist that leads to apoptosis in head and neck squamous cell carcinoma cell lines and is eligible for combination with irradiation.
Kadletz L; Enzenhofer E; Kotowski U; Altorjai G; Heiduschka G
Acta Otolaryngol; 2017 Mar; 137(3):320-325. PubMed ID: 27739348
[TBL] [Abstract][Full Text] [Related]
20. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zhu J; Lv J; Chen J; Zhang X; Ji Y
Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
